Single-source manufacturing and supply dependence
The company relies on third parties for active ingredient, device, encapsulation, and packaging, so any disruption can delay supply and commercialization.
- Scope
- YUTREPIA and L606
- Materiality
- high
Liquidia Corp
Liquidia Corp is a U.S.-based biopharmaceutical company focused on rare cardiopulmonary diseases, especially pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It develops and commercializes inhaled therapies built around its proprietary PRINT particle-engineering platform, with current revenue coming from YUTREPIA and a U.S. profit-sharing promotion agreement with Sandoz.
−31,5 %
−43,5 %
+1 031,2 %
2.01
1.84
| % | |
|---|---|
| Commercial products | 94% Approved and marketed therapies sold directly to patients and providers, led by YUTREPIA. |
| Promotion agreement revenue | 6% Profit-sharing revenue from commercial activities tied to Sandoz Treprostinil Injection in the U.S. |
| Pipeline and platform development | 0% Development of L606 and other PRINT-enabled product opportunities that are not yet commercial. |
Liquidia sells into the U.S. cardiopulmonary specialty care ecosystem, where physicians treat patients with PAH and...
- PAH specialty prescribersprimary
Pulmonary hypertension specialists who prescribe YUTREPIA or support Treprostinil Injection use because of efficacy, convenience, and dosing profile.
- PH-ILD treatment centersprimary
Clinicians treating PH-ILD patients who may adopt YUTREPIA for an inhaled treprostinil option in a difficult disease area.
- Specialty and hospital pharmaciessecondary
Pharmacies that distribute the product and manage fulfillment, reimbursement, and patient access.
- Payers and reimbursement stakeholdersprimary
Commercial and government payors that determine formulary access, rebates, and patient affordability.
- Sandoz commercial partnersecondary
Sandoz buys promotion support and shares profits from Treprostinil Injection sales in the U.S.
Liquidia is overwhelmingly U.S.-centric: YUTREPIA commercialization began in the United States, and the Sandoz...
- •United States is the core commercial market for YUTREPIA
- •U.S. Treprostinil Injection profit share is tied to Sandoz sales
- •Morrisville, North Carolina is the main operating base
- •Laboratory, manufacturing, and office leases support U.S. operations
- •Geographic concentration increases exposure to U.S. reimbursement and litigation
Liquidia’s near-term strategy is to scale YUTREPIA after its May 2025 FDA approval and June 2025 launch, while using a...
01
Scale YUTREPIA commercializationshort-term
Approved product sales are now the main direct revenue engine and must offset development spending.
02
Grow reimbursement and accessshort-term
Adoption depends on payor coverage, gross-to-net performance, and specialty pharmacy execution.
03
Advance pipeline and platform valuemedium-term
L606 and PRINT-based programs are needed to diversify the company beyond a single commercial product.
Liquidia faces high execution risk because it depends on a newly launched product, a narrow disease focus, and...
Commercial launch and reimbursement risk
YUTREPIA is newly launched, so uptake depends on physician adoption, payor coverage, and gross-to-net performance.
- Scope
- U.S. PAH and PH-ILD market
- Materiality
- high
Patent and Hatch-Waxman litigation
505(b)(2) products can face patent disputes that delay approval, restrict labeling, or force costly settlements.
- Scope
- Treprostinil-based products
- Materiality
- high
Financing and dilution risk
The company has significant development and commercialization needs and may need additional capital on unfavorable terms.
- Scope
- Ongoing operations and pipeline funding
- Materiality
- high
Operational concentration in North Carolina
A localized disruption could affect lab, manufacturing, and office operations and is not easily diversified.
- Scope
- Morrisville, North Carolina
- Materiality
- medium
Revenue recognition and gross-to-net deductions
Affects product sales timing and net revenue margin
Promotion agreement revenue estimation
Can cause volatility in service revenue and margins
Manufacturing supply commitments
Affects liquidity and operating flexibility
Operating lease accounting
Affects balance sheet lease liabilities and future cash commitments
Legal proceedings and contingencies
May require reserves or disclosure of contingent liabilities
UNITED THERAPEUTICS Corp
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Vystar Corp
VYST · Fabricated Rubber Products, NEC
Vystar Corp is a U.S.-based company built around two product families: Vytex natural rubber latex materials and RxAir UV-C air purification devices.
Intellia Therapeutics, Inc.
NTLA · In Vitro & In Vivo Diagnostic Substances
Intellia Therapeutics is a clinical-stage biopharmaceutical company built around CRISPR-based gene editing and related delivery technologies.
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
ARROWHEAD PHARMACEUTICALS, INC.
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
ARDELYX, INC.
ARDX · Pharmaceutical Preparations
: 28/04/2026